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Background-—Sex-specific effectiveness of rivaroxaban (RIVA), dabigatran (DABI), and warfarin in reducing myocardial infarction
(MI), heart failure (HF), and all-cause mortality among patients with atrial fibrillation are not known. We assessed sex-specific
associations of RIVA, DABI, or warfarin use with the risk of MI, HF, and all-cause mortality among patients with atrial fibrillation.
Methods and Results-—Medicare beneficiaries (men: 65 734 [44.8%], women: 81 135 [55.2%]) with atrial fibrillation who initiated
oral anticoagulants formed the study cohort. Inpatient admissions for MI, HF, and all-cause mortality were compared between the 3
drugs separately for men and women using 3-way propensity-matched samples. In men, RIVA use was associated with a reduced
risk of MI admissions compared with warfarin use (hazard ratio [95% confidence interval (CI): 0.59 [0.38–0.91]), with a trend
towards reduced risk compared with DABI use (0.67 [0.44–1.01]). In women, there were no significant differences in the risk of MI
admissions across all 3 anticoagulants. In both sexes, RIVA use and DABI use were associated with reduced risk of HF admissions
(men: RIVA; 0.75 [0.63–0.89], DABI; 0.81 [0.69–0.96]) (women: RIVA; 0.64 [0.56–0.74], DABI; 0.73 [0.63–0.83]) and all-cause
mortality (men: RIVA; 0.66 [0.53–0.81], DABI; 0.75 [0.61–0.93]) (women: RIVA; 0.76 [0.63–0.91], DABI; 0.77 [0.64–0.93])
compared with warfarin use.
Conclusions-—RIVA use and DABI use when compared with warfarin use was associated with a reduced risk of HF admissions
and all-cause mortality in both sexes. However, reduced risk of MI admissions noted with RIVA use appears to be limited to men.
( J Am Heart Assoc. 2017;6:e006381. DOI: 10.1161/JAHA.117.006381.)
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A cute myocardial infarction (MI) and heart failure (HF)account for >70% of deaths in patients with nonva-
lvular atrial fibrillation (AF).1 Patients with AF have a 2 to
3 times higher risk of incident HF1–3 and incident MI3,4
compared with patients without AF. Hence, there is a
need for effective strategies to help reduce these
cardiovascular events in patients with AF.5 Furthermore,
there appears to be a sex difference in the incidence of
these cardiovascular events.2 Women with AF have nearly
2 times higher risk for these cardiovascular events when
compared with their male counterparts.2 It is important to
assess sex-specific effectiveness of treatment strategies
that show promise with reducing MI, HF, and all-cause
mortality in patients with AF.
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ORIGINAL RESEARCH
Direct oral anticoagulants (DOAC) (rivaroxaban [RIVA],
dabigatran [DABI]), and warfarin are associated with a
reduction in all-cause mortality and vascular mortality includ-
ing those related to HF hospitalizations in patients with AF.6
Warfarin7 and RIVA8 use are associated with a reduced risk of
MI in this patient population, while evidence regarding the
association between DABI and MI risk is inconsistent.9,10 Data
assessing sex-specific associations of DOACs with the risk of
MI, HF, and all-cause mortality are lacking in the literature.
In order to bridge this literature gap, we used a nationally
representative cohort of elderly Medicare beneficiaries with
newly diagnosed AF to compare outcomes pertaining to
cardiovascular disease (MI and congestive heart failure) and
all-cause mortality in patients taking DOACs (RIVA and DABI)
or warfarin. Relative outcomes for each drug were investi-
gated separately for men and women.
Methods
The study was approved by the University of Iowa Institutional
review board. Since this was a retrospective analysis of claims
data, the need for informed consent was waived.
A description of the methods is mentioned in our prior
work.11 We used the Centers for Medicare and Medicaid
Services patient records and linked data sources including (1)
Beneficiary Summary File Base and Chronic Conditions
segments, (2) Inpatient (Part A) and Carrier (Part B) Standard
Analytic Files for 2011 through 2013, and (3) Pharmacy Drug
Event (Part D) files for 2011–2013. We identified 213 705
Medicare beneficiaries who were enrolled in Centers for
Medicare and Medicaid Services Part D prescription drug
coverage plan, were newly diagnosed with AF between
November 1, 2011 and October 31, 2013, and initiated DABI
150 mg twice daily, RIVA 20 mg once daily, or warfarin within
90 days after AF diagnosis. New AF was defined based on
previously published algorithms (ie, 1 inpatient claim or 2
outpatient claims within 90 days with International Statistical
Classification, 9th Revision, Clinical Modification (ICD-9-CM)
code 427.31 as primary or first secondary diagnosis).12
Medicare Part D benefit plan is a prescription drug plan via
which beneficiaries procure prescription drugs in ambulatory
settings. We note that, for some patients, anticoagulants may
be initiated during hospitalization if AF is diagnosed during an
inpatient stay. These drugs are generally not reflected in Part
D claims, but would be reflected in subsequent medication
fills after discharge. Thus, the 213 705 Medicare beneficiaries
with AF who initiated on 1 of the 3 anticoagulants reflect
outpatient prescriptions for long-term stroke prevention.
From a total of 213 705 Medicare beneficiaries, 5698
were excluded because of incomplete claims data. Another
46 266 patients who were already on oral anticoagulants
before the first AF diagnosis claims date were excluded.
Furthermore, 7931 patients who underwent open heart
surgeries and 6270 patients who underwent joint replace-
ment surgeries or were hospitalized for pulmonary throm-
boembolism or deep vein thrombosis treatment were
excluded. Another 669 patients with mechanical heart valves
or on dialysis were excluded. Our final study cohort
(n=146 871 patients) included 101 715 patients receiving
warfarin (69.4%), 23 177 patients receiving RIVA (15.7%), and
21 979 patients receiving DABI (14.9%).
Outcomes: Inpatient admissions for incident MI, HF, and
all-cause mortality were the outcomes assessed in this study.
MI and HF were based on the primary ICD-9-CM diagnosis on
inpatient standard analytical file claims for acute care stays
(inpatient admissions) occurring after initiating oral anticoag-
ulation. All-cause mortality was defined using the validated
date of death on the Medicare beneficiary enrollment file.
Patient Characteristics were derived from Medicare enroll-
ment data and inpatient and carrier claims. Age, sex, and race
were identified from Medicare enrollment data. Comorbid
diseases defined by Elixhauser et al13 were identified by ICD-
9-CM diagnoses in inpatient and outpatient claims during the
12 months preceding AF diagnosis. We identified additional
comorbidities of importance to AF outcomes, including: other
dysrhythmias (ICD-9-CM codes 427.X, excluding 427.3),
cardiomyopathy (ICD9 codes 425.X), cardiac conduction
disorder (eg, bundle branch block; ICD9 codes 426.X), and
previous implantable cardiac device (eg, pacemaker; ICD9
codes V45.0, V53.3). The CHA2DS2-VASc stroke risk score
was calculated using standard protocol.14 The HAS-BLED
(Hypertension, Abnormal renal and liver functions, Stroke,
Bleeding, Labile INR, Elderly, Drugs or alcohol) score was used
to represent bleeding risk,15 which may impact anticoagulant
Clinical Perspective
What Is New?
• Women with atrial fibrillation have a greater incidence of
myocardial infarction, heart failure, and all-cause mortality
compared with men.
• Rivaroxaban and dabigatran use were associated with
reduced heart failure admissions, and all-cause mortality
in atrial fibrillation patients from both sexes.
• Rivaroxaban’s association with a reduced myocardial infarc-
tion risk seems to be limited to men.
What Are the Clinical Implications?
• Association of rivaroxaban use with reduced myocardial
infarction risk in men may guide clinician decision making
regarding the choice of anticoagulant in men.
• Future studies should explore newer anticoagulants with
superior outcome profile specific to women.
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Table 1. Characteristics of Study Patients Taking Dabigatran (150 mg Twice Daily), Rivaroxaban (20 mg Once Daily), or Warfarin
(Before Propensity Matching)
Women Men
Dabigatran Rivaroxaban Warfarin P Value Dabigatran Rivaroxaban Warfarin P Value
Number of patients 11 239 11 571 58 327 10 740 11 606 43 388
Mean age, y (SD) 76.9 (6.6) 76.6 (6.6) 79.6 (7.2) <0.001 74.7 (5.9) 74.9 (6.0) 76.9 (6.8) <0.001
Number (%)
>85 y
1599 (14.2%) 1565 (13.5%) 16 048 (27.5%) <0.001 749 (6.9%) 906 (7.8%) 6779 (15.6%) <0.001
Race
White, % 9874 (87.9%) 10 342 (89.4%) 50 357 (86.3%) <0.001 9849 (91.7%) 10 677 (92.0%) 38 187 (88.0%) <0.001
Black, % 495 (4.4%) 460 (3.9%) 3525 (6.04%) 273 (2.5%) 284 (2.4%) 1895 (4.4%)
Hispanic, % 496 (4.4%) 492 (4.3%) 2839 (4.9%) 328 (3.1%) 359 (3.1%) 1850 (4.3%)
Other, % 374 (3.3%) 277 (2.4%) 1606 (2.8%) 290 (2.7%) 286 (2.5%) 1456 (3.4%)
Comorbid conditions
Heart failure 2777 (24.7%) 2682 (23.2%) 21 753 (37.3%) <0.001 2533 (23.6%) 2723 (23.5%) 15 945 (36.8%) <0.001
Cardiomyopathy 570 (5.1%) 636 (5.5%) 4536 (7.8%) <0.001 898 (8.4%) 1037 (8.9%) 5216 (12.0%) <0.001
Other dysrhythmia 3676 (32.7%) 3940 (34.1%) 20 690 (35.5%) <0.001 3457 (32.2%) 3798 (32.7%) 15 799 (36.4%) <0.001
Implantable
device
415 (3.7%) 468 (4.0%) 2874 (4.9%) <0.001 621 (5.8%) 814 (7.0%) 3868 (8.9%) <0.001
Peripheral
vascular disease
2042 (18.2%) 2088 (18.1%) 14 262 (24.5%) <0.001 2014 (18.8%) 2247 (19.4%) 11 245 (25.9%) <0.001
Hypertension 9614 (85.5%) 9945 (85.9%) 51 394 (88.1%) <0.001 8785 (81.8%) 9603 (82.7%) 36 058 (83.1%) 0.005
Diabetes mellitus 3554 (31.6%) 3521 (30.4%) 20 892 (35.8%) <0.001 3640 (33.9%) 3947 (34.0%) 17 148 (39.5%) <0.001
Renal disease 945 (8.4%) 868 (7.5%) 12 116 (20.8%) <0.001 1032 (9.6%) 1000 (8.6%) 10 361 (23.8%) <0.001
Liver disease 462 (4.1%) 489 (4.2%) 2751 (4.7%) 0.003 399 (3.7%) 458 (3.9%) 2105 (4.8%) <0.001
Stroke or
transient
ischemic attack
1523 (13.6%) 1443 (12.5%) 10 364 (17.8%) <0.001 1115 (10.4%) 1236 (10.7%) 6609 (15.2%) <0.001
Previous major bleeding
Intracranial 56 (0.5%) 56 (0.5%) 511 (0.88%) <0.001 45 (0.42%) 46 (0.40%) 368 (0.85%) <0.001
Gastrointestinal 3125 (27.8%) 3378 (29.2%) 18 336 (31.4%) <0.001 2452 (22.8%) 2621 (22.6%) 11 006 (25.4%) <0.001
Comorbidity Scores
Gagne Score 3.1 (2.2) 3.0 (2.2) 4.2 (2.8) <0.001 2.9 (2.2) 2.9 (2.2) 4.2 (2.9) <0.001
CHADS2-
VascScore
4.9 (1.5) 4.8 (1.5) 5.4 (1.6) <0.001 3.7 (1.6) 3.8 (1.6) 4.3 (1.7) <0.001
HAS-BLED Score 1.7 1.6 1.8 <0.001 1.6 1.6 1.9 <0.001
Medications in prior 90 days
Statin 4804 (42.7%) 4844 (41.9%) 24 436 (41.9%) 0.234 5038 (46.9%) 5555 (47.9%) 19 564 (45.1%) <0.001
Antiplatelet 523 (4.7%) 486 (4.2%) 3295 (5.7%) <0.001 551 (5.1%) 650 (5.6%) 3157 (7.3%) <0.001
Proton pump
inhibitors
2482 (22.1%) 2593 (22.4%) 14 072 (24.1%) <0.001 1884 (17.5%) 2093 (18.0%) 8045 (18.5%) 0.041
NSAID 1741 (15.5%) 1691 (14.6%) 7416 (12.7%) <0.001 1192 (11.1%) 1279 (11.0%) 4251 (9.8%) <0.001
Prior health services utilization
Inpatient hospital
days
2.7 2.7 5.3 <0.001 2.0 2.1 4.5 <0.001
Number of
prescriptions
9.6 9.6 10.3 <0.001 8.3 8.3 9.0 <0.001
Continued
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choice. The comorbidity score defined by Gagne et al16 was
calculated to assess disease burden. Finally, we identified the
setting of the original AF diagnosis (inpatient or ambulatory
setting).
Statistical Analysis
We divided the total cohort into male and female cohorts. We
used v2 test or 1-way ANOVA, as appropriate, to compare
demographic variables, comorbid conditions, AF diagnosis
setting, medication use, CHA2DS2-VASc score, HAS-BLED
score, and Gagne score between the 3 treatment groups
(participants initiated on DABI 150 mg twice a day [DABI
group], participants initiated on RIVA 20 mg daily [RIVA
group], and participants who were initiated on warfarin
[warfarin group]). Comparisons were conducted separately
in men and women. We then used the 3-way propensity
matching method described by Rassen et al17 to create
groups of patients receiving DABI, RIVA, or warfarin that were
balanced with respect to patient covariates and also had
clinical equipoise—that is, patients included in the matched
samples were plausible candidates for all 3 anticoagulants
under study. Propensity matching was conducted separately
for men and women. We assessed the success of the
matching algorithm by comparing standardized differences in
demographic variables, comorbid diseases, AF diagnosis
setting, medication use, CHA2DS2-VASc score, HAS-BLED
score, and the Gagne score between each drug in the
matched samples. As recommended by Austin18 we evaluated
the success of the matching algorithm using standardized
differences rather than P values, as P values depend on
sample sizes and may therefore not adequately reflect
meaningful differences. Standardized differences <10% (ie,
0.10 times the SD of the difference) suggest adequate
balance.18
We used the propensity matched samples to calculate
event rates/100 patient years of follow-up for each outcome
for the 3 anticoagulant groups in men and women separately.
We then plotted Kaplan–Meier curves for each anticoagulant
for each study outcome in males and females separately. Log-
rank test was performed to compare the curves for the 3
anticoagulants. Finally, we used multivariable Cox propor-
tional hazards regression on the matched samples to further
control for possible differences between treatment groups
within sex. In these models, the dependent variables were
time (in days) from anticoagulant initiation to a given event
(eg, admission for MI or censoring), while candidate indepen-
dent variables included patient demographics, comorbid
conditions, concurrent medication use, and prior health
services utilization as described previously. Censoring events
included end of observation (December 31, 2013), cessation
of the initial anticoagulant (defined as the date of the last fill
plus days supplied), or death. Variables were selected for
inclusion in Cox models based on relationship to the outcome,
using a statistical criterion of 0.05. Covariates adjusted in the
Cox models for each of the outcomes are detailed in Table S1.
Models also included indicators for the type of anticoagulant
used (DABI versus warfarin [reference], RIVA versus warfarin
[reference], and RIVA versus DABI [reference]). Since propen-
sity matching created dependencies in the data, we used
robust standard errors for the Cox regression models. Results
of the regression analyses were reported as hazard ratios and
95% confidence intervals for DABI versus warfarin, RIVA
versus warfarin, and RIVA versus DABI. Data set creation and
propensity matching were conducted using SAS; all other
analysis was performed using STATA 11 software.
Results
Overall, the final study cohort included 23 177, 21 979, and
101 715 patients who initiated RIVA, DABI, and warfarin,
respectively. Of the 65 734 men (44.7%) in the study, 11 606
initiated RIVA, 10 740 initiated DABI, and 43 388 initiated
warfarin. Of the 81 137 women (55.3%), 11 571 initiated
RIVA, 11 239 initiated DABI, and 58 327 initiated warfarin.
Prior to propensity matching, there were significant
Table 1. Continued
Women Men
Dabigatran Rivaroxaban Warfarin P Value Dabigatran Rivaroxaban Warfarin P Value
Skilled nursing
facility
577 (5.1%) 562 (4.9%) 6534 (11.2%) <0.001 269 (2.3%) 278 (2.6%) 2920 (6.7%) <0.001
AF diagnosed in
inpatient setting
5147 (45.8%) 5004 (43.3%) 31 444 (53.9%) <0.001 5015 (46.7%) 4886 (42.1%) 23 559 (54.3%) <0.001
AF indicates atrial fibrillation; CHA2DS2-VASc, 1 point each for congestive heart failure diagnosis, female sex, hypertension diagnosis, diabetes mellitus diagnosis, age 65 to 75 years, and
vascular disease diagnosis; 2 points each for age >75 years and prior stroke or transient ischemic attack; HAS-BLED, 1 point each for hypertension diagnosis, renal disease, liver disease,
stroke history, prior major bleeding, labile international normalized ratio, age >65 years, medication use predisposing to bleeding and alcohol or drug use history; NSAID, nonsteroidal anti-
inflammatory drugs.
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differences in the baseline characteristics across the 3
anticoagulant groups in men as well as women (Table 1).
After propensity matching (Tables 2 through 4), there were
22 827 men (7609 taking each drug), and 33 111 women
(11 037 taking each drug). After propensity matching, there
were no significant differences in the baseline characteristics
Table 2. Standardized Differences (%) Before and After Propensity Matching in Women
Dabigatran vs Rivaroxaban Dabigatran vs Warfarin Rivaroxaban vs Warfarin
Pre-Matching Post-Matching Pre-Matching Post-Matching Pre-Matching Post-Matching
Demographics
Age 4.82% 0.32% 38.27% 0.60% 42.82% 0.90%
Race
White 4.80% 1.97% 4.53% 3.19% 9.33% 1.36%
Black 2.14% 0.77% 7.37% 1.02% 9.49% 0.33%
Other 4.24% 1.82% 0.45% 3.16% 3.79% 1.44%
Comorbid conditions
Heart failure 3.59% 0.87% 27.47% 3.48% 31.10% 2.70%
Cardiomyopathy 1.90% 1.86% 11.05% 0.78% 9.17% 2.44%
Peripheral vascular disease 0.32% 1.18% 15.39% 0.13% 15.71% 0.98%
Hypertension 0.59% 0.46% 8.93% 1.21% 8.34% 1.69%
Diabetes mellitus 2.85% 0.72% 9.18% 1.81% 12.03% 1.11%
Renal disease 3.35% 0.70% 35.57% 0.18% 38.80% 0.37%
Liver disease 0.58% 0.01% 2.95% 2.25% 2.37% 2.24%
Previous stroke or transient ischemic attack 3.21% 1.35% 11.62% 3.60% 14.83% 2.38%
Previous myocardial infarction 1.60% 1.98% 16.86% 1.60% 15.29% 3.32%
Other arrhythmia 2.85% 1.44% 5.84% 2.64% 2.99% 4.05%
Cardiac device 1.83% 2.26% 6.08% 0.85% 4.27% 1.27%
Previous major bleeding
Intracranial hemorrhage 0.20% 0.52% 4.57% 0.55% 4.77% 0.11%
Gastrointestinal hemorrhage 3.08% 1.97% 7.96% 1.71% 4.88% 3.63%
Comorbidity scores
Gagne Score 3.36% 0.35% 43.58% 1.95% 46.84% 2.27%
CHA2DS2-Vasc Score 3.35% 0.58% 33.65% 4.23% 36.99% 4.80%
HAS-BLED Score 2.56% 0.29% 23.14% 4.10% 25.70% 3.85%
Previous healthcare services
Inpatient hospital days 0.84% 1.09% 35.76% 0.12% 35.48% 0.94%
AF diagnosed inpatient 5.11 1.79 16.3% 5.64% 21.45 3.87
Number unique prescription ingredients 1.22% 0.40% 10.48% 0.79% 11.75% 0.40%
Prior extended care or skilled nursing stay 1.27% 0.25% 22.29% 0.23% 23.51% 0.44%
Medications in prior 90 days
Statin 1.78% 1.27% 1.72% 1.03% 0.06% 0.24%
Prescription antiplatelet 2.20% 0.26% 4.51% 0.57% 6.70% 0.34%
Proton pump inhibitors 0.78% 0.98% 4.85% 1.18% 4.06% 2.14%
NSAID 2.45% 1.52% 7.98% 2.14% 5.53% 0.58%
AF indicates atrial fibrillation; CHA2DS2-VASc, 1 point each for congestive heart failure diagnosis, female sex, hypertension diagnosis, diabetes mellitus diagnosis, age 65 to 75 years, and
vascular disease diagnosis; 2 points each for age >75 years and prior stroke or transient ischemic attack; HAS-BLED, 1 point each for hypertension diagnosis, renal disease, liver disease,
stroke history, prior major bleeding, labile international normalized ratio, age >65 years, medication use predisposing to bleeding and alcohol or drug use history; NSAID, nonsteroidal anti-
inflammatory drugs.
DOI: 10.1161/JAHA.117.006381 Journal of the American Heart Association 5
Anticoagulants and Sex-Specific Outcomes Palamaner Subash Shantha et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
between the 3 anticoagulant groups in men (Table 4). Also, in
men, all standardized differences between the 3 anticoagulant
groups were lower than 10%, suggesting a good covariate
match. In women, after propensity matching, statistically
significant differences remained for some comorbid condi-
tions (eg, heart failure, prior stroke). However, all standardized
Table 3. Standardized Differences (%) Before and After Propensity Matching in Men
Dabigatran vs Rivaroxaban Dabigatran vs Warfarin Rivaroxaban vs Warfarin
Pre-Matching Post-Matching Pre-Matching Post-Matching Pre-Matching Post-Matching
Demographics
Age 3.28% 2.56% 34.02% 2.02% 30.71% 4.38%
Race
White 1.07% 1.59% 12.25% 2.53% 13.31% 1.10%
Black 0.61% 0.08% 10.01% 0.50% 10.60% 0.44%
Other 0.85% 1.82% 7.47% 2.69% 8.32% 0.11%
Comorbid conditions
Heart failure 0.29% 0.81% 28.98% 0.12% 29.28% 0.64%
Cardiomyopathy 2.04% 1.22% 12.12% 0.78% 10.09% 1.89%
Peripheral vascular disease 1.55% 0.20% 17.27% 0.76% 15.72% 0.94%
Hypertension 2.48% 0.46% 5.28% 0.43% 2.81% 0.91%
Diabetes mellitus 0.37% 0.58% 12.30% 0.05% 11.94% 0.62%
Renal disease 3.45% 1.74% 38.94% 0.61% 42.29% 0.76%
Liver disease 1.20% 2.74% 5.61% 1.49% 4.42% 1.09%
Previous stroke or transient ischemic attack 0.87% 1.33% 14.55% 3.79% 13.68% 2.55%
Previous myocardial infarction 0.91% 0.80% 18.30% 1.59% 17.39% 0.87%
Other arrhythmia 1.15% 0.59% 8.91% 0.50% 7.76% 0.08%
Cardiac device 5.03% 1.56% 12.03% 0.40% 7.03% 1.80%
Previous major bleeding
Intracranial hemorrhage 0.36% 1.03% 5.41% 0.01% 5.75% 0.84%
Gastrointestinal hemorrhage 0.59% 0.50% 5.93% 0.68% 6.52% 0.18%
Comorbidity scores
Gagne Score 0.80% 0.29% 47.13% 0.71% 46.17% 0.95%
CHA2DS2-Vasc Score 3.88% 1.25% 34.89% 2.63% 31.15% 1.42%
HAS-BLED Score 0.10% 0.62% 30.32% 0.17% 30.25% 0.74%
Previous healthcare services
Inpatient hospital days 0.36% 0.56% 36.13% 1.94% 36.09% 2.31%
Number unique prescription ingredients 0.76% 2.91% 12.45% 1.69% 11.75% 1.10%
Previous extended care or skilled nursing stay 1.75% 0.17% 19.75% 0.25% 21.35% 0.13%
Medications in the prior 90 days
Statin 1.91% 1.82% 3.65% 0.66% 5.56% 2.48%
Prescription antiplatelet 2.09% 0.93% 8.90% 1.36% 6.83% 0.48%
Proton pump inhibitors 1.29% 0.72% 2.60% 0.48% 1.31% 1.19%
NSAID 0.25% 1.34% 4.25% 1.46% 4.00% 0.09%
CHA2DS2-VASc indicates 1 point each for congestive heart failure diagnosis, female sex, hypertension diagnosis, diabetes mellitus diagnosis, age 65 to 75 years, and vascular disease
diagnosis; 2 points each for age >75 years and prior stroke or transient ischemic attack; HAS-BLED, 1 point each for hypertension diagnosis, renal disease, liver disease, stroke history,
prior major bleeding, labile international normalized ratio, age >65 years, medication use predisposing to bleeding and alcohol or drug use history; NSAID, nonsteroidal anti-inflammatory
drugs.
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Table 4. Characteristics of Study Patients Taking Dabigatran (150 mg Twice Daily), Rivaroxaban (20 mg Once Daily), or Warfarin
(After Propensity Matching)
Women Men
Dabigatran Rivaroxaban Warfarin P Value Dabigatran Rivaroxaban Warfarin P Value
No. of patients 11 037 11 037 11 037 7609 7609 7609
Mean age, y (SD) 76.8 (6.2) 76.8 (6.1) 76.9 (6.4) 0.51 74.9 (6.1) 75.1 (6.2) 74.8 (6.1) 0.24
Number (%) >85 y 1522 (13.8) 1565 (14.2) 1598 (14.5) 0.338 626 (8.2) 655 (8.6) 615 (8.1) 0.479
Race
White, % 9756 (88.4) 9825 (89.0) 9874 (89.5) 0.08 6930 (91.2) 6963 (91.5) 6988 (91.8) 0.81
Black, % 471 (4.3) 454 (4.1) 446 (4.0) 205 (2.7) 204 (2.7) 198 (2.6)
Hispanic, % 484 (4.4) 481 (4.4) 449 (4.1) 259 (3.4) 242 (3.3) 235 (3.0)
Other, % 333 (3.0) 277 (2.5) 282 (2.6) 215 (2.8) 191 (2.5) 208 (2.7)
Comorbid conditions
Heart failure 2661 (24.1%) 2620 (23.7%) 2485 (22.5%) 0.014 1898 (24.9%) 1872 (24.6%) 1894 (24.9%) 0.87
Previous myocardial infarction 760 (6.9%) 816 (7.4%) 709 (6.4%) 0.02 792 (10.4%) 810 (10.7%) 832 (10.9%) 0.57
Cardiomyopathy 560 (5.1%) 606 (5.5%) 539 (4.9%) 0.11 668 (8.8%) 694 (9.1%) 650 (8.5%) 0.45
Other dysrhythmia 3632 (32.9%) 3707 (33.6%) 3494 (31.7%) 0.01 2478 (32.6%) 2499 (32.8%) 2496 (32.8%) 0.926
Implantable device 408 (3.7%) 456 (4.1%) 427 (3.9%) 0.24 491 (6.5%) 520 (6.8%) 483 (6.4%) 0.44
Peripheral vascular disease 1979 (17.9%) 2029 (18.4%) 1985 (18.0%) 0.63 1518 (20.0%) 1524 (20.0%) 1494 (19.6%) 0.42
Hypertension 9565 (86.7%) 9582 (86.8%) 9522 (86.3%) 0.47 6389 (84.0%) 6376 (83.8%) 6401 (84.1%) 0.86
Diabetes mellitus 3512 (31.8%) 3475 (31.5%) 3417 (31.0%) 0.38 2732 (35.9%) 2711 (35.6%) 2734 (35.9%) 0.91
Renal disease 889 (8.1%) 868 (7.9%) 882 (8.0%) 0.87 800 (10.5%) 838 (11.0%) 817 (10.7%) 0.61
Liver disease 451 (4.1%) 451 (4.1%) 400 (3.6%) 0.13 325 (4.3%) 285 (3.8%) 302 (4.0%) 0.25
Stroke or transient
ischemic attack
1461 (13.2%) 1411 (12.8%) 1317 (11.9%) 0.02 826 (10.9%) 857 (11.3%) 922 (12.1%) 0.054
Previous major bleeding
Intracranial 54 (0.49%) 50 (0.45%) 49 (0.44%) 0.87 32 (0.42%) 37 (0.49%) 32 (0.42%) 0.78
Gastrointestinal 3072 (27.8%) 3170 (28.7%) 2986 (27.1%) 0.03 1742 (22.9%) 1758 (23.1%) 1764 (23.2%) 0.91
Comorbidity Scores
Gagne Score 3.0 3.1 3.0 0.14 3.1 3.1 3.1 0.644
CHA2DS2-VASc Score 4.8 4.8 4.8 0.711 3.8 3.8 3.8 0.68
HAS-BLED Score 1.6 1.6 1.6 0.091 1.7 1.7 1.7 0.12
Medications in prior 90 days
Statin 4700 (42.6%) 4631 (42.0%) 4644 (42.1%) 0.61 3573 (47.0%) 3504 (46.1%) 3598 (47.3%) 0.29
Antiplatelet 488 (4.4%) 482 (4.4%) 474 (4.3%) 0.90 432 (5.7%) 416 (5.5%) 407 (5.4%) 0.67
Proton pump inhibitors 2435 (22.1%) 2480 (22.5%) 2380 (21.6%) 0.27 1378 (18.1%) 1357 (17.8%) 1392 (18.3%) 0.76
NSAID 1690 (15.3%) 1630 (14.8%) 1608 (14.6%) 0.28 843 (11.1%) 811 (10.7%) 809 (10.6%) 0.61
Prior health services utilization
Hospital days 2.7 2.7 2.7 0.891 2.3 2.3 2.4 0.24
Prescriptions (n) 9.6 9.6 9.5 0.60 8.5 8.3 8.4 0.771
Prior extended care 559 (5.1%) 553 (5.0%) 566 (5.1%) 0.92 226 (3.0%) 228 (3.0%) 230 (3.0%) 0.98
AF diagnosed in inpatient
setting
4987 (45.2%) 4889 (44.3%) 4677 (42.4%) 0.001 2726 (35.8%) 2625 (34.5%) 2725 (35.8%) 0.14
AF indicates atrial fibrillation; CHA2DS2-VASc, 1 point each for congestive heart failure diagnosis, female sex, hypertension diagnosis, diabetes mellitus diagnosis, age 65 to 75 years, and vascular
disease diagnosis; 2 points each for age >75 years and prior stroke or transient ischemic attack; HAS-BLED, 1 point each for hypertension diagnosis, renal disease, liver disease, stroke history, prior
major bleeding, labile international normalized ratio, age >65 years, medication use predisposing to bleeding and alcohol or drug use history; NSAID, nonsteroidal anti-inflammatory drugs.
DOI: 10.1161/JAHA.117.006381 Journal of the American Heart Association 7
Anticoagulants and Sex-Specific Outcomes Palamaner Subash Shantha et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
differences between the 3 anticoagulant groups were sub-
stantially lower than 10%, suggesting good covariate balance.
Outcomes
Sex-specific outcome rates in the propensity-matched cohorts
are detailed in Table 5. Overall, 150 inpatient hospitalizations
for MIs and 751 inpatient hospitalizations for HF were noted
in men, and 507 men died by the end of follow-up. In women,
166 inpatient hospitalizations for MIs and 1295 inpatient
hospitalizations for HF were noted and 659 died by the end of
follow-up.
In men, RIVA use was associated with a reduced risk of MI
admissions compared with warfarin use (hazard ratios [95%
confidence intervals], 0.64 [0.43–0.97]), with a trend toward
low risk compared with DABI use (0.67 [0.44–1.01]; P=0.06)
(Table 6). The risk of MI admissions was similar with DABI use
compared with warfarin use. Furthermore, in men, RIVA use
and DABI use were associated with a reduced risk of HF
admissions (RIVA: 0.75 [0.63–0.89]), (DABI: 0.81 [0.69–0.96])
and all-cause mortality (RIVA: 0.66 [0.53–0.81]), (DABI: 0.75
[0.61–0.93]) compared with warfarin use. The risk of HF
admissions and all-cause mortality were similar with RIVA use
compared with DABI use in men.
In women, the risk of MI admissions was similar across all
3 anticoagulants (Table 6). The risk of HF admissions was
lower with RIVA use and DABI use compared with warfarin use
in women (RIVA: 0.64 [0.56–0.74], DABI: 0.73 [0.63–0.83]),
as was all-cause mortality (RIVA: 0.76 [0.63–0.91], DABI: 0.77
[0.64–0.93]). HF admissions and all-cause mortality did not
differ between RIVA and DABI in women. Figures 1A, 1B, 2A,
2B, 3A and 3B show the associated survival curves (with
embedded graphs showing log-transformed survival rates to
provide visual separation between curves).
Discussion
In our analysis of Medicare claims data for elderly patients with
newly diagnosed AF in the United States, we observed
significant differences in cardiovascular outcomes and all-
cause mortality by anticoagulant type within sex. In men, RIVA
Table 5. Sex-Specific Outcomes in Propensity-Matched Samples Reported as Number of Events (%), Rates/100 Patient-Year of
Follow-Up
Women Men
Dabigatran Rivaroxaban Warfarin Dabigatran Rivaroxaban Warfarin
Number of patients 11 037 11 037 11 037 7609 7609 7609
Myocardial infarction 56 (0.51%) 0.75 51 (0.46%) 0.80 59 (0.53%) 0.80 54 (0.7%) 1.3 38 (0.5%) 0.7 58 (0.8%) 1.2
Heart failure 408 (3.7%) 5.6 345 (3.1%) 5.5 542 (4.9%) 7.6 236 (3.1%) 5.3 227 (3.0%) 4.7 288 (3.8%) 6.1
All-cause mortality 201 (1.8%) 2.6 198 (1.8%) 3.1 260 (2.4%) 3.5 154 (2.0%) 3.4 147 (1.9%) 3.0 206 (2.7%) 4.3
Table 6. Hazard of Outcomes in Matched Cohorts of Men and Women
Women Men
Adjusted Hazard Ratio
(95% Confidence Interval) P Value
Adjusted Hazard Ratio
(95% Confidence Interval) P Value
Myocardial infarction
Rivaroxaban vs warfarin 0.94 (0.65–1.37) 0.76 0.64 (0.43–0.97) 0.03
Dabigatran vs warfarin 0.96 (0.67–1.39) 0.84 0.96 (0.66–1.39) 0.83
Rivaroxaban vs dabigatran 0.98 (0.67–1.43) 0.92 0.67 (0.44–1.01) 0.06
Heart failure
Rivaroxaban vs warfarin 0.64 (0.56–0.74) <0.001 0.75 (0.63–0.89) 0.001
Dabigatran vs warfarin 0.73 (0.63–0.83) <0.001 0.81 (0.69–0.96) 0.02
Rivaroxaban vs dabigatran 0.88 (0.77–1.02) 0.09 0.92 (0.77–1.10) 0.39
All-cause mortality
Rivaroxaban vs warfarin 0.76 (0.63–0.91) 0.004 0.66 (0.53–0.81) <0.001
Dabigatran vs warfarin 0.77 (0.64–0.93) 0.006 0.75 (0.61–0.93) 0.008
Rivaroxaban vs dabigatran 0.98 (0.81–1.20) 0.86 0.81 (0.70–1.10) 0.25
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use was associated with a lower risk of MI compared with either
DABI use or warfarin use, while the risk of MI was similar across
all 3 anticoagulants in women. In both sexes, RIVA use and DABI
use were both associated with lower risk of HF admissions and
all-cause mortality compared with warfarin use.
A reduced risk of MI with RIVA use in patients with AF has
been documented previously.8 The Rivaroxaban–Once-daily,
oral, direct Factor Xa inhibition Compared with vitamin K
antagonism for prevention of stroke and Embolism Trial in
Atrial Fibrillation (ROCKET-AF) trial19 that compared RIVA daily
to warfarin reported a lower rate of incident MI in the RIVA
arm (0.91/100 patient years) compared with the warfarin
arm (1.12/100 patient years). However, sex-specific MI rates
were not reported. The Anti-Xa Therapy to Lower Cardiovas-
cular Events in Addition to Standard Therapy in Subjects With
Acute Coronary Syndrome 2 (ATLAS-ACS 2) trial20 compared
low-dose RIVA (2.5 or 5 mg twice daily) to placebo in patients
with a recent acute coronary syndrome, and found RIVA to
reduce risk of death from cardiovascular causes, MI, and
stroke. The relative impact of RIVA on these outcomes
Figure 1. A, Acute myocardial infarction in men. Survival curves for acute myocardial infarction
comparing the 3 anticoagulants in men with atrial fibrillation. On the right-hand side corners are the curve
separation figures, which are based on log-transformed survival rates. B, Acute myocardial infarction in
women. Survival curves for acute myocardial infarction comparing the 3 anticoagulants in women with atrial
fibrillation. On the right-hand side corners are the curve separation figures, which are based on log-
transformed survival rates.
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combined did not differ significantly by sex. However, direct
comparisons to our analysis cannot be drawn because of
differences in the patient populations (patients with recent
acute coronary syndrome versus patients with AF in our
study), different RIVA dose and timing (RIVA 2.5 or 5 mg twice
daily versus RIVA 20 mg daily in our study), and different
comparators (placebo versus warfarin and DABI in our study).
Inconsistencies exist with regard to the association
between DABI use and risk of MI in patients with AF.
Randomized trials report an increased MI risk with DABI use
compared with warfarin use10 and platelet activation potential
of DABI is suspected to be the etiology of this increased MI
risk.10 In contrast, observational data suggest a reduced MI
risk with DABI use when compared with warfarin use.9,21 Sex-
specific comparisons of DABI use compared with warfarin use
and the associated risk of MI were not reported in these
studies.
While previous studies have evaluated the risk of MI
between RIVA and warfarin, or between DABI and warfarin,
few studies have compared RIVA use to DABI use. One meta-
Figure 2. A, Heart failure in men. Survival curves for heart failure comparing the 3 anticoagulants in men
with atrial fibrillation. On the right-hand side corner is the curve separation figure, which is based on log-
transformed survival rates. B, Heart failure in women. Survival curves for heart failure comparing the 3
anticoagulants in women with atrial fibrillation. On the right-hand side corner is the curve separation figure,
which is based on log-transformed survival rates.
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analysis found that RIVA use was associated with a reduced
MI risk compared with DABI use in patients with AF,22 while
another observational analysis found similar risk of MI in
patients with AF using RIVA or DABI.23 These reports did not
mention sex-specific comparisons of RIVA to DABI and
associated MI risk.
Compared with MI prevention, the use of anticoagulants
for HF has received little attention in the literature. RIVA is
thought to have the potential to prevent HF episodes.
Specifically, RIVA inhibits Factor Xa, an enzyme necessary
for thrombin generation. Recent molecular studies have
identified thrombin-related pathways that simulate myocyte
injury, enhance myocardial inflammation, promote endothe-
lial dysfunction, and increase microvascular thrombo-
sis.24,25 This milieu is suspected to orchestrate HF
pathogenesis. By inhibiting steps preceding thrombin
generation, RIVA is suspected to inactivate the abovemen-
tioned thrombin cascade.24,25 With this underlying hypoth-
esis, the Rivaroxaban in Reducing the Risk of Death,
Myocardial Infarction or Stroke in Participants With Heart
Failure and Coronary Artery Disease Following an Episode
of Decompensated Heart Failure (COMMANDER-HF) trial26
is assessing the efficacy of RIVA in reducing HF readmis-
sions as a secondary end point among patients with HF
Figure 3. A, All-cause mortality in men. Survival curves for all-cause mortality comparing the 3
anticoagulants in men with atrial fibrillation. On the right-hand side corner is the curve separation figure,
which is based on log-transformed survival rates. B, All-cause mortality in women. Survival curves for all-
cause mortality comparing the 3 anticoagulants in women with atrial fibrillation. On the right-hand side
corner is the curve separation figure, which is based on log-transformed survival rates.
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and coronary artery disease. DABI, a direct thrombin
inhibitor, may also have similar benefits,24,25 but human
experiments are not yet evaluating this hypothesis. In our
study, we noted that both RIVA use and DABI use were
associated with a reduction in HF risk compared with
warfarin in men as well as women with AF, thereby adding
validity to the thrombin hypothesis discussed above.
With regard to all-cause mortality, in harmony with our
results, prior investigations have consistently shown an
association between reduction in all-cause mortality with
RIVA use6,19,23 as well as DABI use,9,10 compared with
warfarin use in patients with AF. The mechanistic basis
remains unclear and multiple hypotheses exist. Thrombin
cascade inhibition mentioned above is one such hypothesis,
while improved stroke and MI prevention with RIVA or DABI
may also explain reductions in mortality. Selection bias is also
possible because healthier individuals are more likely to be
prescribed DOACs and hence have a survival advantage over
warfarin candidates. Furthermore, in concordance with our
results, RIVA use is shown to be similar to DABI use in terms
of risk for all-cause mortality in observational studies.23,27
However, none of these referenced studies reported sex-
specific outcomes.
Limitations
Although the strengths of our analysis include nationally
representative large sample of patients, and the use of
propensity score matching to control for confounders, several
limitations must be noted. Bias because of unmeasured
confounders is still a possibility since propensity matching will
not control for unmeasured confounders. In addition, our data
include patients >65 years of age only, and therefore our
findings may not generalize to younger patients. Also, the
Medicare claims used for this study lack granular prognostic
details such as AF burden, AF type, left ventricular ejection
fraction, and degree of coronary artery disease. Furthermore,
patients hospitalized for AF may have had troponin elevation
because of the mechanism of demand–supply mismatch and
could have received a diagnosis of MI. This is a known
limitation of ICD-9-based MI outcome determination because
ICD-9 codes cannot differentiate MI caused by demand–
supply mismatch and MI caused by plaque rupture.28
Similarly, hospitalization for AF could have had a clinical
presentation of HF and hence such hospitalizations could
have received a primary diagnosis of HF.29 Making such a
distinction, although important, is beyond the scope of our
data. Prospective studies with validated MI and HF outcome
determination are needed to improve specificity of these
outcomes. Finally, we had a short follow-up (median
14 months) and hence it is yet to be determined whether
these associations will stand with long-term follow-up.
Conclusions
Sex differences are possible in the association between oral
anticoagulant use and the risk of MI, HF, and all-cause
mortality in patients with AF. Our finding that RIVA use may
reduce the risk of MI in men may guide clinician decision
making regarding the choice of anticoagulant in men with AF.
Although it is reassuring to note that the DOACs are
associated with a reduced risk of HF and all-cause mortality
in both sexes, our results also confirm the enormity of
cardiovascular disease burden in women and the need for
newer treatment strategies with proven benefit specific to
women.
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Supplemental Material 
 
Table S1. Covariates included in the Cox-regression models for each of the outcomes 
 Covariates 
AMI Age, race, diabetes, hypertension, previous MI, 
previous TIA/stroke, prescription antiplatelet use 
HF Age, race, diabetes, hypertension, previous MI, prior 
heart failure diagnosis, 
All-cause mortality Age, race, diabetes, previous MI, previous TIA/stroke, 
previous heart failure, 
 
 
